Ugne Sabale (Sweden)
MSD Sweden COREPoster Author Of 1 e-Poster
PD108 - COST IMPLICATION OF INTRODUCING A FULLY LIQUID READY-TO-USE PEDIATRIC HEXAVALENT VACCINE IN NORWAY (ID 541)
Session Name
0340 - Poster Discussion Session 06: Vaccine I (ID 7)
Presenter